A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson�s disease who have fallen.
Read time: 1 mins
Last updated:1st May 2012
This study seeks to assess the benefit of rivastigmine (a drug which augments mental function) on gait (walking) dysfunction in patients with Parkinson�s disease (PD) with a past history of a fall. The primary aim is to determine the effect of the cholinesterase inhibitor (ChEi) rivastigmine on step time variability in patients with PD. Step time variability is a marker of how stable an individual's walking is and a prognostic marker for future falls risk.
|Study start date||2012-05-01|